Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: entradatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2026 | Buy → Neutral | H.C. Wainwright | |
| 4/1/2026 | Overweight | Cantor Fitzgerald | |
| 2/11/2026 | $20.00 | Buy | Guggenheim |
| 1/28/2026 | $21.00 | Outperform | Oppenheimer |
| 12/6/2024 | $29.00 | Buy | ROTH MKM |
| 1/5/2024 | $22.00 | Outperform | Oppenheimer |
| 4/3/2023 | $25.00 | Buy | H.C. Wainwright |
| 11/24/2021 | Outperform | Evercore ISI Group | |
| 11/23/2021 | Outperform | Cowen & Co. | |
| 11/23/2021 | $29.00 | Neutral | Goldman Sachs |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4/A - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
DEF 14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
S-8 - Entrada Therapeutics, Inc. (0001689375) (Filer)
10-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
EFFECT - Entrada Therapeutics, Inc. (0001689375) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright downgraded Entrada Therapeutics from Buy to Neutral
Cantor Fitzgerald initiated coverage of Entrada Therapeutics with a rating of Overweight
Guggenheim initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $20.00
Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $21.00
ROTH MKM initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $29.00
Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00
H.C. Wainwright initiated coverage of Entrada Therapeutics with a rating of Buy and set a new price target of $25.00
Evercore ISI Group initiated coverage of Entrada Therapeutics with a rating of Outperform
Cowen & Co. initiated coverage of Entrada Therapeutics with a rating of Outperform
Goldman Sachs initiated coverage of Entrada Therapeutics with a rating of Neutral and set a new price target of $29.00
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
Fastest customizable press release news feed in the world
-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation from 5 mg/kg in Cohort 1. ELEVATE-45-201 is a Phase 1/2 MAD clinical study
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units ("RSUs") to three newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest qua
-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026, as well as ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026 -- -- Cash runway expected into Q3 2027 with $255 million in cash, cash equivalents and marketable securities as of March 31, 2026 -- -- Entrada to host investor webcast and conference call today, Thursday, May 7, at 8:30 a.m. ET -- BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the first quarter ended Ma
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo -- -- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- -- Consequently, Cohort 1 demonstrated an increase of 2.36% in dystrophin over a baseline of 4.00% and an increase of 2.31% in exon skipping over a baseline of 2.66% in treated participants -- -- Statistically s
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company's website at www.entradatx.com. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and availab
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 12,990 restricted stock units ("RSUs") to two newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of March 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest qua
-- Patients in Cohort 1 have progressed to the open label, Phase 2 portion of ELEVATE-44-201 -- -- Company on track to report ELEVATE-44-201 Cohort 1 data in Q2 2026, with Cohort 2 data by end of year -- BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients who completed dosing in Cohort 1 of the double-blinded, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiation of Cohort 2 at 12 mg/kg, a dose escalation from 6 mg/kg in Cohort 1. ELEVATE-44-201 is
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the Company will participate in two upcoming investor conferences. Guggenheim Emerging Outlook: Biotech Summit 2026Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, February 11, 2026, at 4:00 p.m. Eastern Time in New York, NY. TD Cowen 46th Annual Health Care Conference Dipal Doshi, Chief Executive Officer, will participate in a fireside chat on Tuesday, March 3, 2026, at 2:30 p.m. Eastern Time in Boston, MA. Live webcasts will be available on the Investor Relations section of the Company's website at www.entradatx.com. Replays will be available on the
-- Company on track to report ELEVATE-44-201 data from the first cohort in Q2 2026 and ELEVATE-45-201 data from the first cohort in mid-2026 – -- Expects to initiate global Phase 1/2 MAD clinical study of ENTR-601-50 by the end of 2026 and to submit global regulatory applications for ENTR-601-51 in 2026 – -- Expands pipeline with selection of ENTR-801 as first clinical candidate in ocular diseases for the treatment of Usher syndrome type 2A and expects to nominate second clinical candidate in 2026 – -- Cash runway into Q3 2027 – -- Entrada to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET) -- BOSTON, Jan. 08, 2026
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 PM PT (6:45 PM ET). A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage int
Live Leadership Updates
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and Kiran Patki, MD, MSc, FFPM, as Senior Vice President of Clinical Development -- -- Cash runway expected into Q2 2027 with $354 million in cash, cash equivalents and marketable securities as of June 30, 2025 -- BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) to
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. "We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan's deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "I'm honored to join the Board of Entrada
āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ:TRDA). "Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical companies," said Pankaj Bhargava, M.D., Chief Executive Officer of āshibio. "Under Dipal's leadership, Entrada has advanced its innovative pipeline of intracellular therapeutics into the clinic, completed multiple private financings,
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. "Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Wit
- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 -- Cash runway into the second half of 2025 - BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates. "In the first quarter, we successfully closed on our transformational collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1, the most prev
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Dr. Bernhardt "Bernie" Zeiher to its Board of Directors, effective immediately. Dr. Zeiher served most recently as the Chief Medical Officer at Astellas Pharma. "Bernie is a dynamic life sciences leader and we look forward to having him join our Board of Directors," said Dipal Doshi, President and Chief Executive Officer of Entrada. "As the former Chief Medical Officer and President of Development at
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced the appointment of Karla MacDonald as Chief Corporate Affairs Officer, effective immediately. Ms. MacDonald previously served as Entrada's Vice President of Corporate Communications and Investor Relations. She remains a member of the Entrada executive team and will report to Dipal Doshi, Entrada's President and Chief Executive Officer. "Karla is a transformational leader who has already demonstrated her value as a membe
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately. "We are thrilled to recognize the appointment of Jared to General Counsel," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "Since joining Entrada, Jared has been critical in leading our legal and compliance functions, guiding us through our recent financings and building a robust patent estate covering
Live finance-specific insights
-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026, as well as ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026 -- -- Cash runway expected into Q3 2027 with $255 million in cash, cash equivalents and marketable securities as of March 31, 2026 -- -- Entrada to host investor webcast and conference call today, Thursday, May 7, at 8:30 a.m. ET -- BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the first quarter ended Ma
-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo -- -- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- -- Consequently, Cohort 1 demonstrated an increase of 2.36% in dystrophin over a baseline of 4.00% and an increase of 2.31% in exon skipping over a baseline of 2.66% in treated participants -- -- Statistically s
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company's website at www.entradatx.com. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and availab
This live feed shows all institutional transactions in real time.
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13D/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G/A - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)
SC 13G - Entrada Therapeutics, Inc. (0001689375) (Subject)